Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPN-6602 Monotherapy and in Combination With Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT06433947Phase 1Recruiting
- Sponsor
- Opna Bio
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of OPN-6602 in multiple myeloma (MM) (3 arms), sponsored by Opna Bio. Primary endpoints: Dose-limiting toxicities at 30 days, Treatment-emergent adverse events at 30 days and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
OPN-6602
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06433947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433947.